EGFR and non-small cell lung carcinoma: Of the 194 NSCLC samples tested, 25 (12.8%) were positive for EGFR mutations (including a sample with a double mutation (EGFR_ex20 c.2360A > C; p. (Gln787Pro) (Q787P)/EGFR_ex20 c.2369C > T; p. (Thr790Met) (T790M)) and 169 negatives (87.2%) using NGS, the benchmark analysis (Figure 1).